MILAN (ITALPRESS) – Regeneron, a company active in the field of biotechnology that produces innovative treatments for people suffering from serious diseases, strengthens its position in Italy with the opening of new offices in Milan, confirming the country as one of the priority markets within the international expansion strategy of the company, started in 2021. Founded in 1988 by doctors-sciencers Leonard Schleifer and George Yancopoulos, still leading the company, Regeneron has built over 35 years a distinctive business model in the global biotech landscape, based on a long history of innovation, a rigorous scientific approach and a strategy that always puts the patient at the centre. The result is that most of the drugs (almost 100%), approved and developing, are made internally in the company’s laboratories and millions of people worldwide are treated with a Regeneron drug, a goal that testifies the real impact of the company’s innovations. In addition, Regeneron’s drugs are now available in more than 100 countries and 50 of them are undergoing clinical studies, proof of the company’s commitment to excellence in global research and inclusive science. Approved in Italy in 2023, Regeneron now has about 120 employees in the two business units of onco-ematology and immunology, more than 30 active clinical studies and important collaborations with academic institutions. The new offices confirm and consolidate its presence in the Italian economic and health system and the desire to continue in its constant commitment to bring science closer to patients. “The opening of our new headquarters in Milan is a further step in the global expansion of Regeneron and confirms the centrality of Italy in our strategic vision,” says Andrea Musilli, Country Manager Oncology & Hematology and Site Head of Regeneron in Italy. “This is also reflected in the continued growth of the Italian team capable of gaining the trust and credibility of all stakeholders to whom we address, whether they are representatives of the scientific community or institutions.” The new Milanese headquarters, strategically located in a modern and sustainable building, will act as a central hub for Italian operations. The context in which it is located, in a strategically redeveloped area like that of the Central Station places Regeneron in the center of a dynamic international and innovative ecosystem, which will support the further growth of the expected organic for the next years. “The inauguration of the new headquarters in Milan is an important sign for the territory. The presence and consolidation of a leading company in the biopharmaceutical sector in Lombardy Region confirm the strategic value of investments in research and innovation, generating development, employment with high added value and economic growth for the benefit of the community and the country system”, comments Marco Alparone, Vice President and Councillor for Budget and Finance, Regione Lombardia. With one of the highest reinvestment rates in research and development in the sector (in 2025, it allocated around 30% of its turnover, amounting to $5.9 billion) Regeneron offers an effective example of strategy in long-term biotechnology, business growth driven by innovation and global market impact. Its ability to constantly translate science into medicine has led to the development of 14 drugs made internally, of which 9 are approved at national level – and Regeneron markets 2 for oncologic and immunological treatments. This thanks to a proprietary technological portfolio that accelerates the development of innovative treatments, including the VelociSuite platform, and the Regeneron Genetics Center (RGC) which, with more than 3 million sequential exoms, is one of the largest and most diversified inizgenetic sequencing iatives in the world. “The entry into Italy of a recognised international player is always a positive signal for our healthcare system. It represents an opportunity to speed up innovation, enhancing and harmonizing the relationship between public and private, with the aim of ensuring access to fair and homogeneous care throughout the territory, an essential requirement to give concrete answers to patients and their dissatisfied needs,” says Gian Antonio Girelli, Member XII Social Affairs Commission, Chamber of Deputies. “Science and people guide our corporate culture, our “special ingredient” that inspires all our activities both inside and outside”, says Elisabetta Bramani, Country Manager Immunology of Regeneron in Italy. Innovation in Regeneron is not an end to itself but serves to transform science into medicine by offering concrete answers to the therapeutic needs still unsatisfied with those who live with serious diseases, keeping the patient always at the center.” Innovation, we read in a note, “is part of the DNA of Regeneron, fed by a culture that is based on two fundamental pillars: science and people. The constant commitment to “doing good, doing good” is reflected in applying science to improve people’s lives, promoting a culture of integrity and excellence and building sustainable communities.” Throughout the year, Regeneron encourages and supports its employees to engage in social work through volunteer programs, pro bono activities and donations. The company is also included in the Dow Jones Sustainability World Index. Regeneron allocates over 90% of its social impact investments to support STEM education at local, national and international level, claiming to be one of the companies that most support the sector in the world. In Italy it supports the Federation of Scientific and Technical Associations (FAST) and, among the leading initiatives, the Regeneron ISEF (International Science and Engineering Fair), the most prestigious international scientific competition for young talents. Since 2020, Regeneron’s STEM partnerships have supported more than 4 million students worldwide. -photo press office Regeneron –(ITALPRESS).
